Biopsy of the prostate - The urge to search for a new standard

Central European Journal of Urology

Volumn 63, Issue 4, 2010, Pages 166-175

  Antoniewicz, Artur A ^a   Zapala, Lukasz ^a   Borówka, Andrzej ^a   de Reijke, Theo M ^b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy of the prostate; MRI guided biopsy; Prostate cancer diagnosis; TRUS guided TruCut biopsy

Indexed keywords

EID: 79960673905     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2010.04.art1     Document Type: Article

References (101)

1. Wojciechowska U, Zatoński, J: Cancers in Poland in 2006. Centrum Onkologii-Instytut 2006, pp. 49-127.
2. Fried NM: New laser treatment approaches for benign prostatic hyperplasia. Curr Urol Rep 2007; 8: 47-52.
3. Epstein JI, Walsh PC, Sauvageot J, Carter HB: Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158: 1886-1890.
4. Fleshner NE, O'Sullivan M, Fair WR: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158: 505-508; discussion 508-509.
5. Rabbani F, Stroumbakis N, Kava BR et al: Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159: 1247-1250.
6. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954.
7. Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151: 1571-1574.
8. Roehrborn CG, Pickens GJ, Sanders JS: Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 1996; 47: 347-352.
9. Ellis WJ, Brawer MK: Repeat prostate needle biopsy: Who needs it? J Urol 1995; 153: 1496-1498.
10. Stav K, Judith S, Merald H et al: Does prostate biopsy gleason score accurately express the biologic features of prostate cancer? Urol Oncol 2007; 25: 383-386.
11. Altay B, Kefi A, Nazli O et al: Comparison of gleason scores from sextant prostate biopsies and radical prostatectomy specimens. Urol Int 2001; 67: 14-18.
12. Xia T, Dong J, Zhang J: Gleason scores of prostate needle biopsy specimens and of radical prostatectomy specimens, a comparative study. Zhonghua Yi Xue Za Zhi 2002; 82: 1604-1605.
13. Djavan B, Kadesky K, Klopukh B et al: Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict gleason scores of radical prostatectomy specimens. Eur Urol 1998; 33: 261-270.
14. Young HH DD: Young's practice of urology. Philadelphia, WB Saunders 1926; 2: 414-512.
15. Bianchi F: Practical advantages of the perineal biopsy of the prostate. J Urol 1956; 76: 645-650.
16. Parry WL, Finelli JF: Biopsy of prostate. J Urol 1960; 84: 643-648.
17. Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-74; discussion 74-75.
18. Silletti JP, Gordon GJ, Bueno R et al: Prostate biopsy: Past, present, and future. Urology 2007; 69: 413-416.
19. Stamey TA: Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2-12.
20. Ravery V, Goldblatt L, Royer B et al: Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000; 164: 393-396.
21. Norberg M, Egevad L, Holmberg L et al: The sextant protocol for ultrasoundguided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562-566.
22. Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion 202-193.
23. Nava L MF, Consonni P, Scattoni V et al: Results of a prospective randomized study comparing 6, 12, 18 transrectal ultrasound guided sextant biopsies in patients with elevated PSA, normal dre and normal prostatic ultrasound. J Urol 1997; 157 (Suppl): 59A.
24. Babaian RJ, Toi A, Kamoi K, Troncoso P et al: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-157.
25. Presti JC Jr., Chang JJ, Bhargava V, Shinohara K: The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial. J Urol 2000; 163: 163-166; discussion 166-167.
26. Naughton CK, Miller DC, Mager DE et al: A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: Impact on cancer detection. J Urol 2000; 164: 388-392.
27. Gore JL, Shariat SF, Miles BJ et al: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 1554-1559.
28. Klein EA, Zippe CD: Transrectal ultrasound guided prostate biopsy--defining a new standard. J Urol 2000; 163: 179-180.
29. Presti JC, Jr: Prostate biopsy: How many cores are enough? Urol Oncol 2003; 21: 135-140.
30. Heidenreich A, Aus G, Bolla M et al: [Eau guidelines on prostate cancer]. Actas Urol Esp 2009; 33: 113-126.
31. Pepe P, Panella P, D'Arrigo L, Savoca F, Pennisi M, Aragona F: Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review. Oncology 2006; 70: 81-89.
32. Kawachi MH, Bahnson RR, Barry M et al: Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 714-736.
33. Mohler J, Babaian RJ, Bahnson RR et al: Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 650-683.
34. Schroder FH: Review of diagnostic markers for prostate cancer. Recent Results Cancer Res 2009; 181: 173-182.
35. Roobol MJ, Kerkhof M, Schroder FH et al: Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the european randomised study of screening for prostate cancer (erspc). Eur Urol 2009; 56: 584-591.
36. Catalona WJ, Smith DS, Ratliff TL et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
37. Brawer MK, Chetner MP, Beatie J et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-845.
38. Djavan B: Prostate biopsies and the vienna nomograms. Eur Urol Supl 2006; 5: 500-510.
39. Djavan B, Zlotta A, Remzi M et al: Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J Urol 2000; 163: 1144-1148; discussion 1148-1149.
40. Ukimura O, Durrani O, Babaian RJ: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997; 50: 66-72.
41. Letran JL, Blase AB, Loberiza FR et al: Repeat ultrasound guided prostate needle biopsy: Use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol 1998; 160: 426-429.
42. Morgan TO, McLeod DG, Leifer ES et al: Prospective use of free psa to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl 1996; 7: 58-63.
43. Filella X, Truan D, Alcover J et al: Comparison of several combinations of free, complexed, and total psa in the diagnosis of prostate cancer in patients with urologic symptoms. Urology 2004; 63: 1100-1103; discussion 1103-1104.
44. Okihara K, Ukimura O, Nakamura T et al: Complexed psa improves prostate cancer detection: Results from a multicenter japanese clinical trial. Urology 2006; 67: 328-332.
45. Sozen S, Eskicorapci S, Kupeli B et al: Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 25 and 20 ng/ml: Results of a prospective multicenter study. Eur Urol 2005; 47: 302-307.
46. Ung JO, San Francisco IF, Regan MM et al: The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 2003; 169: 130-135.
47. Weaver RP NM, Weigle JW: Correlation of ultrasound guided and digitally directed transrectal biopsies of palpable prostatic abnormalities. J Urol 1991; 145: 516-518.
48. Antoniewicz AA, Huzarski T, Keller E et al: Biopsy of the prostate. Clinical urology series. Toruń, 2002, Chapt 3, pp. 71-80.
49. Ficarra V, Novella G, Novara G et al: The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol 2005; 48: 932-937.
50. Karakiewicz PI, Bazinet M, Aprikian AG et al: Outcome of sextant biopsy according to gland volume. Urology 1997; 49: 55-59.
51. Guichard G, Larre S, Gallina A et al: Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007; 52: 430-435.
52. Scattoni VZA, Nava L, Roscigno M, Montorsi F, Rigatti P: Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and trus prostatic lesionguided biopsies. Eur Urol Supl 2002; 1: 21-27.
53. Goła{ogonek}b A SM, Gliniewicz B, Sikorski A: Prospective evaluation of the results of initial sextant and saturative biopsies. Urol Pol 2006; 59 (suppl. 1): 15-20.
54. Eskicorapci SY, Baydar DE, Akbal C et al: An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444-448; discussion 448-449.
55. Eskicorapci SY, Guliyev F, Akdogan B et al: Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173: 1536-1540.
56. Inahara M, Suzuki H, Kojima S et al: Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology 2006; 68: 815-819.
57. Djavan B, Ravery V, Zlotta A et al: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 2001; 166: 1679-1683.
58. Chang JJ, Shinohara K, Bhargava V, Presti JC, Jr: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998; 160: 2111-2114.
59. Puppo P, Introini C, Calvi P, Naselli A: Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer. Eur Urol 2006; 49: 873-878.
60. Bauer JJ, Zeng J, Weir J et al: Three-dimensional computer-simulated prostate models: Lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999; 53: 961-967.
61. Hong YM, Lai FC, Chon CH et al: Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22: 7-10.
62. Rabets JC, Jones JS, Patel A, Zippe CD: Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004; 172: 94-97.
63. Chun FK, Briganti A, Graefen M et al: Development and external validation of an extended repeat biopsy nomogram. J Urol 2007; 177: 510-515.
64. Loch T: Computerized transrectal ultrasound (C-TRUS) of the prostate: Detection of cancer in patients with multiple negative systematic random biopsies. World J Urol 2007; 25: 375-380.
65. Sedelaar JP, Vijverberg PL, de Reijke TM et al: Transrectal ultrasound in the diagnosis of prostate cancer: State of the art and perspectives. Eur Urol 2001; 40: 275-284.
66. Partin AW, Stutzman RE: Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy. Urol Clin North Am 1998; 25: 581-589, viii.
67. Melchior SW, Brawer MK: Role of transrectal ultrasound and prostate biopsy. J Clin Ultrasound 1996; 24: 463-471.
68. Chen ME, Troncoso P, Johnston DA et al: Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997; 158: 2168-2175.
69. Mitterberger M, Pinggera GM, Horninger W et al: Comparison of contrast enhanced color doppler targeted biopsy to conventional systematic biopsy: Impact on gleason score. J Urol 2007; 178: 464-468; discussion 468.
70. Remzi M, Dobrovits M, Reissigl A et al: Can power doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? Eur Urol 2004; 46: 451-456.
71. Pallwein L, Mitterberger M, Pinggera G et al: Sonoelastography of the prostate: Comparison with systematic biopsy findings in 492 patients. Eur J Radiol 2008; 65: 304-310.
72. Braeckman J, Autier P, Garbar et al: Computer-aided ultrasonography (histoscanning): A novel technology for locating and characterizing prostate cancer. BJU Int 2008; 101: 293-298.
73. Braeckman J, Autier P, Soviany C et al: The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 2008; 102: 1560-1565.
74. Andriole G, Bullock T, Belani J et al: Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. J Urol Suppl 2007; 70 (6): 22-26.
75. Megwalu, II, Ferguson GG, Wei JT et al: Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008; 102: 546-550.
76. Taneja SS: Prostate biopsy: Targeting cancer for detection and therapy. Rev Urol 2006; 8: 173-182.
77. Bullock T, Traxel E, Belani J: Evaluation of targetscan™ system inprostate cancer detection [poster 223]. Presented at the Annual Meeting of the American Urological Society; May 21-26, 2005; San Antonio, TX 2005.
78. Balogh E DA, Susil RC: Visualization, planning, and monitoring software for mri-guided prostate intervention robot. Proc Intl Soc Mag Reson Med 2006; 14: 21-26
79. Beyersdorff D, Winkel A, Hamm B et al: MR imaging-guided prostate biopsy with a closed mr unit at 1.5 t: Initial results. Radiology 2005; 234: 576-581.
80. DiMaio SP, Pieper S, Chinzei K et al: Robot-assisted needle placement in open MRI: System architecture, integration and validation. Comput Aided Surg 2007; 12: 15-24.
81. Mazzucchelli R, Scarpelli M, Cheng L et al: Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Res 2009; 29: 5155-5161.
82. Algaba F, Montironi R: Impact of prostate cancer multifocality on its biology and treatment. J Endourol 2010; 24: 799-804.
83. Onik G, Barzell W: Transperineal 3d mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008; 26: 506-510.
84. de la Rosette J, Ahmed H, Barentsz J et al: Focal therapy in prostate cancer-report from a consensus panel. J Endourol 2010; 24: 775-780.
85. Giannarini G, Autorino R, Valent F et al: Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: A randomized, controlled trial. J Urol 2009; 181: 585-591; discussion 591-583.
86. Kabay S, Sahin L, Yucel M: Caudal block anaesthesia for transrectal biopsy of prostate in patients with anal rectal disorders. CEJurol 2009; 1 (62): 15-20.
87. Toren P, Razik R, Trachtenberg J: Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies. Can Urol Assoc J 2010; 4: E12-14.
88. Weber B, Saliken J, Jadavji T et al: A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker. Can Urol Assoc J 2008; 2: 543-545.
89. Moore CK, Karikehalli S, Nazeer T et al: Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005; 173: 70-72.
90. Egevad L, Algaba F, Berney DM et al: Handling and reporting of radical prostatectomy specimens in europe: A web-based survey by the european network of uropathology (enup). Histopathology 2008; 53: 333-339.
91. Stock C, Hruza M, Cresswell J, Rassweiler JJ: Transrectal ultrasound-guided biopsy of the prostate: Development of the procedure, current clinical practice, and introduction of self-embedding as a new way of processing biopsy cores. J Endourol 2008; 22: 1321-1329.
92. Billis A, Guimaraes MS, Freitas LL et al: The impact of the 2005 international society of urological pathology consensus conference on standard gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008; 180: 548-552; discussion 552-543.
93. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL: The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
94. Uemura H, Hoshino K, Sasaki T et al: Usefulness of the 2005 international society of urologic pathology gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int 2009; 103: 1190-1194.
95. Wellmann A, Wollscheid V, Lu H et al: Analysis of microdissected prostate tissue with proteinchip arrays--a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 2002; 9: 341-347.
96. Wright GL, Jr: Seldi proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002; 2: 549-563.
97. Bueno R, Loughlin KR, Powell MH, Gordon GJ: A diagnostic test for prostate cancer from gene expression profiling data. J Urol 2004; 171: 903-906.
98. Porkka KP, Visakorpi T: Molecular mechanisms of prostate cancer. Eur Urol 2004; 45: 683-691.
99. Sorensen KD, Orntoft TF: Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010; 10: 49-64.
100. Alcaraz A HP, Tubaro A, Schroder FH, Castro R: Is there evidence of a relationship between benigh prostate hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009; 55: 864-875.
101. Clements R: Ultrasound-guided prostate biopsy in 2005. Clin Radiol 2006; 61: 140-141.